Product Details
Those who know Tarceva should know that this drug is a special drug for the treatment of cancer. As long as the drug is taken, precautions should be taken, so as to ensure the efficacy and safety of the drug. The efficacy of Tarceva is good, but there are still many precautions. Let’s learn more about the precautions of Tarceva!
Tarceva C for pancreatic cancer or other solid tumors receiving Erlot Serious interstitial lung disease-like events, including fatal cases, have occasionally been reported in patients treated with TIX. In the randomized monotherapy C trial (see Clinical Trials), the incidence of interstitial lung disease-like events in the maintenance study was .% in the erlotinib group and % in the placebo group, second/third-line treatment The incidence of interstitial lung disease-like events in the study (%) was the same in the erlotinib and placebo groups. In combination with gemcitabine in pancreatic cancer trials (see Clinical Trials), the incidence of interstitial lung disease-like events was .% in the erlotinib + gemcitabine group and .% in the placebo + gemcitabine group.
The overall incidence of interstitial lung disease-like events in all patients treated with erlotinib in all trials (including trials without a control group and trials with combination chemotherapy) was approximately .%.
Diagnostic reports of patients with suspected ILD-like events include pneumonia, radiation pneumonitis, hypersensitivity pneumonitis, interstitial pneumonia, interstitial lung disease, bronchiolitis obliterans, pulmonary fibrosis, acute respiratory distress syndrome, pulmonary infiltrates, and alveolitis. Symptoms appeared days to months (median days) after taking erlotinib. Most cases are associated with other causes of interstitial lung disease, such as concurrent or previous chemotherapy, previous radiation therapy, pre-existing interstitial lung disease, metastatic lung disease, or pulmonary infection.
In the event of new acute exacerbations or progressive unexplained pulmonary symptoms such as dyspnea, cough, and fever, erlotinib therapy should be temporarily discontinued during diagnostic evaluation. Once the diagnosis is (interstitial lung disease), erlotinib treatment should be stopped and appropriate treatment should be given if necessary (see [Adverse Reactions] and [Dosage and Dosage])
Diarrhea, dehydration, electrolyte imbalance and renal failure
Patients receiving erlotinib may develop diarrhea, and moderate or severe diarrhea should be treated with loperamide. Some patients may require dose reduction. For severe or persistent dehydration-related diarrhea, nausea, anorexia or vomiting, patients need to discontinue the drug and take appropriate treatment measures for dehydration (see [Adverse Reactions]). Hepatorenal syndrome, acute renal failure (including death), and renal insufficiency have been reported in patients receiving erlotinib. Some are caused by baseline liver injury, and some are related to dehydration from diarrhea, vomiting, and/or anorexia or concomitant chemotherapy. Severe dehydration with hypokalemia and renal failure (including fatal) has occurred rarely, mainly in patients receiving concurrent chemotherapy.
For patients with severe diarrhea or persistent diarrhea, or even dehydration, especially those with high risk factors (such as receiving concurrent chemotherapy, having other symptoms or diseases, or other basic factors including older age) group of patients), erlotinib therapy should be interrupted and appropriate measures should be taken to provide intravenous fluid rehydration to the patient. For dehydrated patients, renal function and blood electrolytes, including serum potassium, should be monitored while rehydrating. It is recommended to regularly monitor the renal function and serum electrolytes of patients at risk of dehydration (see [Adverse Reactions]).
Disclaimer
The information/pictures/parameters, etc. displayed on this webpage about【The latest version of India Tarceva direct mail India Tarceva purchasing agent 13621079267】are provided by member【Beijing Xiangrui Import and Trade Technology Co., Ltd.
】,By Titker Trade Network members 【Beijing Xiangrui Import and Trade Technology Co., Ltd.
】is solely responsible for the authenticity, accuracy and legality of the information/pictures/parameters, etc.,Titker Trade Network only provides display services. For your safety, please choose Titker Trade Network for online trading, otherwise Titker Trade Network will not bear any responsibility for this.
If your legitimate rights and interests have been infringed, please contact Titker Trade Network customer service as soon as possible. We will serve you wholeheartedly. Thank you for your attention and support to Titker Trade Network!